IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that its preliminary unaudited revenue for the third quarter ended September 30, 2018 is expected to be in the range of $34.3 million to $34.7 million. Also, based on current business trends, […]
Other News
Shape Memory Medical Names Scott Kraus as Vice President of Sales and Business Development
SANTA CLARA, Calif.–(BUSINESS WIRE)–Shape Memory Medical Inc. announced today that Scott Kraus has joined the Company as its Vice President of Sales and Business Development. Scott most recently served as the Area Vice President – East for Intersect ENT, a position he has held since October of 2014. Prior to […]
BD Breaks Ground at I.D.E.A. Tempe Campus
TEMPE, Ariz., Oct. 3, 2018 /PRNewswire/ — Officials from BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, were joined today by Gov. Doug Ducey, Tempe Mayor Mark Mitchell and representatives of The Boyer Company to officially break ground on the new I.D.E.A. (Innovation, Discovery, Education and Arts) Tempe campus. BD Peripheral Intervention will be the first […]
Dr. Ori Ben-Yehuda joins CardioVascular BioTherapeutics, Inc. as Chief Medical Officer
DALLAS, Oct. 2, 2018 /PRNewswire/ — CardioVascular BioTherapeutics, Inc. (“CVBT” or the “Company”) is pleased to welcome Ori Ben-Yehuda, MD, FACC as our new Chief Medical Officer (CMO). “Dr. Ben-Yehuda brings leading edge skills and demonstrated drug development success to the Company. He will guide our clinical team in our current and future development […]
V-Wave Announces Enrollment of First Patients in RELIEVE-HF Pivotal Trial of its Heart Failure Therapy
CAESAREA, Israel, Oct. 3, 2018 /PRNewswire/ — V-Wave Ltd. announced today that it has enrolled the first patients in its global, 500 patient pivotal study of its proprietary, minimally invasive implanted interatrial shunt device for treating patients with NHYA Class III and ambulatory Class IV symptomatic heart failure (HF). This randomized, controlled, double-blinded […]
Trial Results of Mesoblast Cell Therapy in End-Stage Heart Failure Selected as Late-Breaking Presentation at 2018 American Heart Association Scientific Sessions
NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-controlled Phase 2b trial evaluating its allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM in the treatment of end-stage heart failure patients implanted with a left ventricular assist device (LVAD) has […]
Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures
LAVAL, Québec, Oct. 01, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), today announced its election to issue common shares to the holders of its outstanding convertible debentures in satisfaction of interest payable. In accordance with the terms of its outstanding convertible […]
Zenosense, Inc.: MIDS Medical Expands Technical Team
VALENCIA, SPAIN, Oct. 02, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Zenosense, Inc. (OTCQB: ZENO, “Zenosense”, the “Company”), a healthcare technology company focused on the development and commercialization of the MIDS Cardiac™ hand-held technology for the early detection of heart attack at the Point of Care, is pleased to announce […]
Hancock Jaffe Appoints Three New Independent Directors
IRVINE, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) — Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a company specializing in medical devices that restore cardiac and vascular health, announced today that it has appointed accomplished medical device professionals Dr. Francis Duhay and Dr. Sanjay Shrivastava, and recognized fund manager and equity […]
Biotricity Provides Fiscal 2018 Second Quarter Updates for Shareholders
REDWOOD CITY, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) — Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, today provided operational updates for its fiscal 2018 second quarter which ended September 30, 2018. Bioflux 1.0 sales growth and market expansion achieved a record high during the fiscal 2018 second quarter; the […]



